

**SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16 OF  
THE SECURITIES EXCHANGE ACT OF 1934**

*For the month of May 2019*

---

**ANCHIANO THERAPEUTICS LTD.**

(Translation of registrant's name into English)

---

**1/3 High-Tech Village, Givat Ram, P.O. Box 39264  
Jerusalem, 9139102 Israel**

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

**Form 20-F**       **Form 40-F**

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:

**Yes**       **No**

---

---

On May 22, 2019, Anchiano Therapeutics Ltd. announced its first quarter 2019 financial results. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

<b>Exhibit No.</b>	<b>Description of Exhibit</b>
--------------------	-------------------------------

---

99.1	Press Release dated May 22, 2019
------	----------------------------------

---

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Anchiano Therapeutics Ltd.**

By: /s/ Dr. Frank G. Haluska

Dr. Frank G. Haluska  
Chief Executive Officer

Dated May 22, 2019

---